Recent Updates
Recently added Catalysts
WHWK Positive Sentiment Score: 70/100

Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to...

Key Takeaway: Whitehawk Therapeutics, Inc. will present at the Jefferies 2025 Global Healthcare Conference from June 3-5, 2025, in New York City. CEO Dave Lennon will provide an overview of the company's activities on June 4. The event will include a live webcast accessible for those interested in the company's advanced cancer treatments which utilize innovative technology. This presentation highlights Whitehawk's commitment to enhancing oncology therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a notable healthcare conference expected to enhance visibility.
  • Company showcasing advanced technologies in cancer treatment.
  • Opportunity to discuss innovative ADC portfolio targeting difficult cancers.

Full Press Release Details

MORRISTOWN, N.J. , May 28, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK ), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today its presentation at the Jefferies 2025 Global Healthcare Conference, taking place June 3-5, 2025, in New York City, NY. Dave Lennon, PhD, President and CEO, will present a company overview on Wednesday, June 4, 2025, from 2:00-2:30 PM ET .
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact: [email protected]
SOURCE Whitehawk Therapeutics, Inc.

21 %

Frequently Asked Questions

When is Whitehawk Therapeutics presenting at the Jefferies conference?

Whitehawk Therapeutics will present on June 4, 2025, from 2:00-2:30 PM ET.

How can I access the live webcast of the presentation?

The live webcast can be accessed on the Whitehawk Therapeutics IR website.

What type of company is Whitehawk Therapeutics?

Whitehawk Therapeutics specializes in oncology therapeutics using advanced technologies.

What kind of portfolio does Whitehawk Therapeutics have?

They have an advanced three-asset ADC portfolio for treating difficult cancers.

What is the source of Whitehawk's therapeutic assets?

The assets are in-licensed from WuXi Biologics under an exclusive agreement.

Last updated: May 28, 2025